Chemotherapy in the Treatment of Non-Small Cell Lung Cancer

References

• American Cancer Society. Cancer Statistics 1985 1985; 35(1)19–56
   Google Scholar
• Simes R. Risk-benefit relationships in cancer clinical trials: The ECOG experience in non-small cell lung cancer. J Clin Oncol 1985; 3(4)462–412
   PubMed Web of Science ®Google Scholar
• Stanley K. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65(1)25–32
   PubMed Web of Science ®Google Scholar
• Aisner J, Hansen H. Commentary: Current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 1981; 65(11–12)979–986
   PubMedGoogle Scholar
• O'Connell J, Kris M, Gralla R, et al. Analysis of factors predicting outcome in 350 patients with stage in non-small cell lung cancer receiving high-dose cisplatin/vinca alkaloid regimens. Proc Am Soc Clin Oncol 1985; 4: 190
   Google Scholar
• Comis R. The use of Adriamycin in lung cancer. Adriamycin: Its Expanding Role in Cancer Treatment, M Ogawa, F Muggia, M Rozencweig. Excerpta Medica, Amsterdam 1984; 165–182
   Google Scholar
• Bakowski M, Crouch J. Chemotherapy of non-small cell lung cancer: A reappraisal and a look to the future. Cancer Treat Rev 1983; 10: 159–172
   PubMed Web of Science ®Google Scholar
• Muggia F, Blum R, Foreman J. Role of chemotherapy in the treatment of lung cancer; evolving strategies for non-small cell histologies. Int J Radial Oncol Biol Phys 1984; 10: 137–145
   Web of Science ®Google Scholar
• Hoffman P, Bitran J, Golomb H. Chemotherapy of metastatic non-small cell bronchogenic carcinoma. Semin Oncol 1983; 10(4)111–122
   PubMedGoogle Scholar
• Livingston R. Combination chemotherapy of bronchogenic carcinoma non-oat cell. Cancer Treat Rev 1977; 4: 153–165
   PubMed Web of Science ®Google Scholar
• Selawry O S, Hansen H H. Lung cancer. Cancer Medicine, J F Holland, E Frei. Lea and Febiger, Philadelphia 1977; 1737
   Google Scholar
• Kreisman H, Ginsberg S, et al. Iproplatin or carboplatin in extensive non-small cell lung cancer. Proc Am Soc Clin Oncol 1985; 4: 186
   Google Scholar
• Wolf J, Hyde L, Phillips R, . Recent comparative trials of systemic therapy in non-small cell carcinoma of the lung. Lung Cancer: Progress in Therapeutic Research, F Muggia, M Rozencweig, et al. Raven Press, New York 1979; 375–382
   Google Scholar
• Luedke D, Luedke S, Petruska P, et al. A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer. Cancer 1983; 51: 778–782
   PubMed Web of Science ®Google Scholar
• Lad T E, Nelson R B, Diekamp U, et al. Immediate versus postponed combination chemotherapy (CAMP) for unresectable non-small cell lung cancer: A randomized trial. Cancer Treat Rep 1981; 65: 973–978
   PubMedGoogle Scholar
• Cormier Y, Bergeron D, La Forge J, et al. Treatment of non-small cell lung cancer. The benefits of polychemotherapy. Am Rev Respir Dis Part 2 1981; 123(4)105
   Google Scholar
• Vogl S E, Mehta C R, Cohen M, et al. MACC chemotherapy for adenocarcinoma and epidermoid carcinoma of the lung. Low response rate in cooperative group studies. Cancer 1979; 44: 864–868
   PubMed Web of Science ®Google Scholar
• Eagan R, Ingle J, Frytak S, et al. Platinum based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep 1977; 61(7)1339–1345
   PubMedGoogle Scholar
• Eagan T, Frytak S, Creagn E, et al. Phase II study of cyclophosphamide, adriamycin, and cis-dichlorodiammineplatinum by infusion in patients with adenocarcinoma and large cell carcinoma of the lung. Cancer Treat Rep 1979; 63(9–10)1589–1591
   PubMedGoogle Scholar
• Brittel J, Eagan T, Ingle J, et al. Cis-dichlorodiammineplatinum (II) alone followed by adriamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophosphamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 1978; 62(8)1207–1210
   PubMedGoogle Scholar
• Evans W, Feld R, De Boer G, et al. Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma. Cancer Treat Rep 1981; 65(11–12)947–954
   PubMedGoogle Scholar
• Davis S, Ramobbi P, Park Y. Combination cyclophosphamide, doxorubicin, and cisplatin chemotherapy for extensive non-small cell carcinomas of the lung. Cancer Treat Rep 1981; 65(11–12)955–958
   PubMedGoogle Scholar
• Robert F, Omura G, Birch R, et al. Randomized Phase III comparison of three doxorubicin based chemotherapy regimens in advance non-small cell lung cancer: A Southern Cancer Study Group Trial. J Clin Oncol 1984; 2(5)391–395
   PubMed Web of Science ®Google Scholar
• Ruckdeschel J, Finkelstein D, Mason B, et al. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: Est 2575, Generation V, A randomized comparison of four cisplatin containing regimens. J Clin Oncol 1985; 3(1)72–79
   PubMed Web of Science ®Google Scholar
• Bodey G, Lagakos S, Gutierrez A, et al. Therapy of advanced squamous carcinoma of the lung. Cyclophosphamide versus COMB. Cancer 1977; 39: 1026–1031
   PubMed Web of Science ®Google Scholar
• Livingston R B, Heilbrun L, Lehane D, et al. Comparative trial of combination chemotherapy in extensive squamous cell carcinoma of the lung: A Southwest Oncology Group study. Cancer Treat Rep 1977; 61: 1623–1629
   PubMedGoogle Scholar
• Ruckdeschel J C, Mehta C, Salazar O, et al. Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, Generation III, HAM versus CAMP. Cancer Treat Rep 1981; 69: 959–963
   Google Scholar
• Gralla R, Casper E, Kelsen D, et al. Cisplatin and vindesine combination chemotherapy for advance carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414–420
   PubMed Web of Science ®Google Scholar
• Itri L, Gralla R, Kelsen D, et al. Cisplatin, vindesine and bleomycin combination chemotherapy of advanced non-small cell lung cancer. Cancer 1983; 51: 1050–1055
   PubMed Web of Science ®Google Scholar
• Woods R, Levi Page J, et al. Non-small cell lung cancer: A randomized comparison of chemotherapy with no chemotherapy. Proc Am Soc Clin Oncol 1985; 4: 177
   Google Scholar
• Dhingra H, Valdivieso M, Carr D, et al. Randomized trial of three combinations of cisplatin with vindesine and or VP-16–213 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 1985; 3(2)176–183
   PubMed Web of Science ®Google Scholar
• Green M, Steepler M, Anderson J, et al. Vinblastine and cisplatin chemotherapy in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1985; 4: 176
   Google Scholar
• Mitrou P, Graubner M, Berdel W, et al. Cis-platinum (DDP) and VP 16–213 (etoposide) combination chemotherapy for advanced non-small cell lung cancer. A phase II clinical trial. Eur J Clin Oncol 1984; 20(3)347–351
   PubMedGoogle Scholar
• Joss R, Alberto P, Obrecht J. Combination chemotherapy for non-small cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. Cancer Treat Rep 1984; 68(9)1079–1084
   PubMedGoogle Scholar
• Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. Cancer 1982; 50: 2751–2756
   PubMed Web of Science ®Google Scholar
• Klastersky J, Sculier J, Nicaise C, et al. Combination chemotherapy with cisplatin, etoposide and vindesine in non-small cell lung cancer. A clinical trial of the EORTC lung cancer working party. Cancer Treat Rep 1983; 67(7–8)
   Google Scholar
• Einhorn L, Williams S, Loehrer P, et al. Phase III random prospective study of vindesine versus vindesine + high dose (120 mg/m2) platinum versus vindesine + platinum (60 mg/m2) + mitomycin-C in non-small cell lung cancer. Proc Am Soc Clin Oncol 1985; 4: 176
   Google Scholar
• Kalman L, Kriss M, Gralla R, et al. Vinca alkaloid and cisplatin combination chemotherapy in non-small cell lung cancer: Result of a randomized trial with a comparison of methods of response assessment in 109 patients. Proc Am Soc Clin Oncol 1983; 2: 201
   Google Scholar
• Kris M, Gralla R, Casper E, et al. Complete response with chemotherapy in non-small cell lung cancer: An analysis of patient characteristics, survival and relapse patterns. Proc Am Soc in Oncol 1983; 2: 202
   Google Scholar